NRx Pharmaceuticals, Inc. (NRXP) News
Follow NRx Pharmaceuticals, Inc. (NRXP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
NRx Pharmaceuticals Receives FDA Approval for Preservative-Free Ketamine
NRx Pharmaceuticals said the FDA approved its preservative-free ketamine application ahead of the agency’s November 10 goal date.
REGULATION | Nov 02, 2026, 01:13 PM UTC
L
NRx Pharmaceuticals completes ketamine manufacturing validation
NRx Pharmaceuticals announced completion of manufacturing process validation and two-year stability for preservative-free ketamine.
EQUITY | Oct 19, 2026, 12:30 PM UTC
L
NRx Pharmaceuticals receives FDA labeling review letter for preservative-free ketamine
NRx Pharmaceuticals announced receipt of an FDA labeling review letter for preservative-free ketamine.
REGULATION | Oct 15, 2026, 12:27 PM UTC
M
NRX Pharma Wins $11.2M DARPA Contract For Depression Trial
NRX Pharmaceuticals' subsidiary, NRx Defense Systems, has secured a prime contract with DARPA valued at approximately $11.2 million to conduct the SPARC-TMS clinical trial for treatment-resistant depression. Initially, a
EQUITY | Oct 05, 2026, 09:04 PM UTC
L
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
MIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- NRx Defense Systems, (“NRx Defense”, “NRXD” or “Company” an NRx Pharmaceuticals, Inc. NASDAQ:NRXP subsidiary company, today announced the award of an initial $11,177,757.27 contr
NEWS | Sep 30, 2026, 11:09 AM UTC
L
NRx Pharmaceuticals, Inc. (NRXP) Wins $11.18M DARPA Contract
NRx Pharmaceuticals’ subsidiary NRx Defense Systems received a $11,177,757 DARPA prime contract to evaluate robotic TMS with NRX-101 for treatment-resistant depression in a trial that will now begin enrolling.Material De
NEWS | Sep 30, 2026, 11:09 AM UTC
H
NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are not deployable in op
LIVE | Sep 30, 2026, 11:02 AM UTC
M
NRx Pharma FDA reclassifies ketamine ANDA amendment as minor
NRx Pharmaceuticals said the FDA moved its preservative-free ketamine (NRX-100) ANDA amendment from major to minor and set a GDUFA goal date of Nov. 10, 2026, adding it will not require substantial FDA resources.
REGULATION | Sep 15, 2026, 07:13 PM UTC
L
NRX Pharmaceuticals Price Target Maintained With a $10.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 06:51 PM UTC
L
NRx Pharmaceuticals to participate in three September investor conferences
NRx Pharmaceuticals said its management team will participate in three upcoming investor conferences in September 2026.
EQUITY | Sep 08, 2026, 11:07 AM UTC
L
NRXP - NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
NRXP - NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 08, 2026, 11:01 AM UTC
L
NRX Pharmaceuticals reports first-half 2026 net loss narrows
NRX Pharmaceuticals reported a first-half 2026 net loss of $18.0 million, improved from $23.1 million a year earlier, and said cash rose to $26.7 million at June 30, 2026.
EARNINGS | Aug 17, 2026, 09:11 PM UTC
L
NRx Pharmaceuticals reports Q2 2026 financial results; call Aug 17
NRx Pharmaceuticals (Nasdaq:NRXP) reports second quarter 2026 financial results and provides a corporate update, with a conference call scheduled for Monday, August 17 at 4:30pm ET.
EARNINGS | Aug 17, 2026, 11:00 AM UTC
L
NRXP - FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certific
NRXP - FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
REGULATION | Aug 07, 2026, 11:00 AM UTC
M
NRx Pharmaceuticals Responds
NRx Pharmaceuticals issues statement in response to Kadima allegations, citing arbitration over non-acquisition by HOPE Therapeutics
EQUITY | Jun 25, 2026, 08:07 PM UTC
M
NRx Pharma Treats Patients
NRx Pharma's HOPE Therapeutics treats first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System
EQUITY | Jun 25, 2026, 11:10 AM UTC
M
NRXP Treats Patients
NRx Pharmaceuticals' subsidiary HOPE Therapeutics treats first patients using Zeta Surgical's FDA-cleared Zeta TMS navigation system
EQUITY | Jun 25, 2026, 11:00 AM UTC
L
NRXP Treats First Patient
NRXP's Zeta Surgical announces successful treatment of first patient with Zeta TMS Navigation System at HOPE Therapeutics
EQUITY | Jun 23, 2026, 03:06 PM UTC
H
NRXP: FDA Approves Expanded Access
NRx Pharma announces FDA approval of intermediate population expanded access protocol for NRX-101
EQUITY | Jun 22, 2026, 11:15 AM UTC
M
NRXP Expands Access Protocol
NRx Pharmaceuticals announces FDA grant of expanded access protocol for use of D-Cycloserine-based NRX-101 for augmentation of transcranial magnetic stimulation in the treatment of depression
EQUITY | Jun 22, 2026, 11:01 AM UTC